On the basis of the current evidence, we hypothesized that ILs (IL-1β, 6, 8, 10) and tissue damage biomarkers (CRP, CK) could be reliable markers for surgical invasiveness in the treatment of PFs, and we verified if any correlation existed between their serum values and the surgical device used to treat PF. The gene discussed is CRP; the disease is pemphigus foliaceus.